{
  "question_stem": {
    "en": "A new antiarrhythmic medication (drug A) is tested in a series of experiments that measure the flow of ions responsible for producing an action potential in cardiac muscle cells. Ion flow is measured before and after the drug is administered, and the results are shown in the chart below (each colored line represents a different type of ion) {{exhibit_1}}.",
    "zh": "一项新的抗心律失常药物（药物 A）在一系列实验中进行测试，该实验测量产生心肌细胞动作电位的离子流。 在给药前后测量离子流，结果如下图所示（每条彩色线代表一种不同类型的离子） {{exhibit_1}}。"
  },
  "question": {
    "en": "Drug A has an antiarrhythmic effect most similar to which of the following drugs?",
    "zh": "药物 A 的抗心律失常作用与以下哪种药物最相似？"
  },
  "options": {
    "A": {
      "en": "Adenosine",
      "zh": "腺苷"
    },
    "B": {
      "en": "Digoxin",
      "zh": "地高辛"
    },
    "C": {
      "en": "Dofetilide",
      "zh": "多非利特"
    },
    "D": {
      "en": "Esmolol",
      "zh": "艾司洛尔"
    },
    "E": {
      "en": "Flecainide",
      "zh": "氟卡尼"
    },
    "F": {
      "en": "Lidocaine",
      "zh": "利多卡因"
    },
    "G": {
      "en": "Quinidine",
      "zh": "奎尼丁"
    },
    "H": {
      "en": "Verapamil",
      "zh": "维拉帕米"
    }
  },
  "correct_answer": "C",
  "explanation": {
    "en": "The recorded action potential shows the typical profile of non-pacemaker cardiac cells, which includes the following phases:\n\n1.  Phase 0 (rapid depolarization) – occurs when the resting membrane potential reaches threshold; is characterized by rapid sodium entry into the cell due to activation and opening of voltage-dependent sodium channels.\n2.  Phase 1 (early repolarization) – caused primarily by activation of transient outward potassium currents along with a rapid decline in inward sodium current.\n3.  Phase 2 (plateau phase) – stable membrane potential due to a balance of late inward calcium current (L-type channels) and outward potassium current.\n4.  Phase 3 (late repolarization) – characterized by the opening of additional potassium channels (delayed-rectifier potassium currents) and continued efflux of potassium ions from the cell; this is in conjunction with the decay of inward calcium current.\n5.  Phase 4 (resting) – normal resting membrane potential is between –80 mV and –95 mV, and it is generated by outward potassium flow through potassium leak channels open at rest. The Na+-K+-ATPase pump allows the potassium and sodium gradients to be maintained across the membrane.\n\nThe ion flow graph after drug A administration shows a decrease in outward potassium flow from the myocyte during phase 3 repolarization of the myocardial action potential. Class III antiarrhythmic drugs (eg, amiodarone, sotalol, dofetilide) predominantly block potassium channels and inhibit the outward potassium currents during phase 3 of the cardiac action potential, thereby prolonging repolarization and total action potential duration {{exhibit_2}}.\n\n(Choice A) Adenosine stimulates A1 receptors on the surface of cardiac cells, activating potassium channels and increasing potassium conductance, which causes the membrane potential to remain negative for a longer period. This results in transient slowing of the sinus rate and increased atrioventricular (AV) nodal conduction delay.\n\n(Choice B) Digoxin inhibits the Na+-K+-ATPase pump in myocardial cells, resulting in an increase in intracellular sodium, which leads in turn to a rise in intracellular calcium concentration. Digoxin does not affect potassium channels and has minimal effect on potassium efflux from myocardial cells during the action potential.\n\n(Choice D) Esmolol is a rapid-acting, short-duration beta blocker (class II antiarrhythmic) that slows the rate of discharge of sinus or ectopic pacemakers and increases the refractory period of the AV node. It has no effect on potassium efflux from myocardial cells.\n\n(Choices E, F, and G) Class IA (procainamide, quinidine), IB (lidocaine), and IC (flecainide) antiarrhythmic drugs inhibit sodium-dependent (phase 0) depolarization and slow conduction. Class IA and IC agents also have some potassium-blocking activity and can cause prolongation of the action potential (seen mostly with class IA agents). However, all class I drugs have prominent sodium channel-blocking activity, which would blunt the blue tracing in the above graph.\n\n(Choice H) Calcium channel blockers (eg, verapamil, diltiazem) inhibit the L-type calcium channels during phase 2 of the myocardial action potential and phase 0 of the pacemaker action potential. They slow the sinus rate, prolong conduction through the AV node, and depress myocardial contractility.",
    "zh": "记录的动作电位显示了非起搏心肌细胞的典型特征，其中包括以下几个阶段：\n\n1.  0 相（快速去极化）——当静息膜电位达到阈值时发生；其特征是由于电压依赖性钠离子通道的激活和开放，导致钠离子快速进入细胞。\n2.  1 相（早期复极化）——主要由瞬时外向钾离子电流的激活以及内向钠离子电流的快速下降引起。\n3.  2 相（平台期）——由于晚期内向钙离子电流（L 型通道）和外向钾离子电流之间的平衡，膜电位保持稳定。\n4.  3 相（晚期复极化）——其特征是附加钾离子通道（延迟整流钾离子电流）的开放以及钾离子持续从细胞中流出；这与内向钙离子电流的衰减有关。\n5.  4 相（静息）——正常静息膜电位在 –80 mV 和 –95 mV 之间，它由通过静息时开放的钾离子漏通道的外向钾离子流产生。 Na+-K+-ATP 酶泵允许跨膜维持钾离子和钠离子梯度。\n\n药物 A 给药后的离子流图显示，在心肌动作电位的 3 相复极化期间，心肌细胞的外向钾离子流减少。 III 类抗心律失常药物（例如，胺碘酮、索他洛尔、多非利特）主要阻断钾离子通道，并在心肌动作电位的 3 相期间抑制外向钾离子电流，从而延长复极化和总动作电位持续时间 {{exhibit_2}}。\n\n（选项 A）腺苷刺激心肌细胞表面的 A1 受体，激活钾离子通道并增加钾离子电导，这导致膜电位保持负电位更长时间。 这会导致窦性心律的短暂减慢和房室 (AV) 结传导延迟的增加。\n\n（选项 B）地高辛抑制心肌细胞中的 Na+-K+-ATP 酶泵，导致细胞内钠离子增加，进而导致细胞内钙离子浓度升高。 地高辛不影响钾离子通道，并且对心肌细胞在动作电位期间的钾离子外流影响很小。\n\n（选项 D）艾司洛尔是一种快速起效、短效的 β 受体阻滞剂（II 类抗心律失常药），可减慢窦性或异位起搏器的放电率，并增加房室结的难治期。 它对心肌细胞的钾离子外流没有影响。\n\n（选项 E、F 和 G） I 类抗心律失常药物（普鲁卡因胺、奎尼丁）、IB 类（利多卡因）和 IC 类（氟卡尼）抑制钠依赖性（0 相）去极化并减缓传导。 I 类和 IC 类药物也具有一些阻断钾离子的活性，并可导致动作电位的延长（主要见于 I 类药物）。 然而，所有 I 类药物都具有显着的钠离子通道阻滞活性，这将削弱上图中蓝色描记的线条。\n\n（选项 H）钙通道阻滞剂（例如，维拉帕米、地尔硫卓）在心肌动作电位的 2 相和起搏器动作电位的 0 相期间抑制 L 型钙离子通道。 它们会减慢窦性心律、延长通过房室结的传导并抑制心肌收缩力。"
  },
  "summary": {
    "en": "This question tests knowledge of cardiac action potentials and the mechanism of action of antiarrhythmic drugs, specifically Class III agents like dofetilide. It requires interpreting ion flow graphs to determine which drug has a similar effect on potassium channels during phase 3 repolarization.\n\nTo solve this question, understand the phases of the cardiac action potential and the role of potassium channels in phase 3. Recognize that Class III antiarrhythmics block potassium channels, prolonging repolarization. Match the drug's effect on ion flow to the mechanism of action of the antiarrhythmic classes.",
    "zh": "这个问题测试了对心脏动作电位和抗心律失常药物作用机制的了解，特别是多非利特等 III 类药物。 它需要解释离子流图以确定哪种药物在 3 相复极化期间对钾离子通道具有相似的作用。\n\n要解决这个问题，请了解心脏动作电位的各个阶段以及钾离子通道在 3 相中的作用。 认识到 III 类抗心律失常药物会阻断钾离子通道，从而延长复极化。 将药物对离子流的影响与抗心律失常药物类别的作用机制相匹配。"
  },
  "tags": "Cardiac action potential; Antiarrhythmic drugs; Class III antiarrhythmics; Dofetilide; Potassium channels; Phase 3 repolarization; Electrophysiology; Cardiology; Pharmacology",
  "category": "CVS",
  "question_id": "901",
  "has_exhibits": true,
  "exhibit_count": 3,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg",
    "image3.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\901",
  "extracted_at": "2025-11-05T12:19:37.003782",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:32:30.553062",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}